You Yijie, Niu Yunlian, Zhang Jian, Huang Sheng, Ding Peiyuan, Sun Fengbing, Wang Xuhui
Department of Neurosurgery, Xinhua Hospital Chongming Branch, Shanghai, China.
Department of Neurology, Xinhua Hospital Chongming Branch, Shanghai, China.
Front Pharmacol. 2022 Aug 25;13:927083. doi: 10.3389/fphar.2022.927083. eCollection 2022.
U0126, as an inhibitor of the MAPK signaling pathway, is closely related to various biological processes, such as differentiation, cell growth, autophagy, apoptosis, and stress responses. It makes U0126 play an essential role in balancing cellular homeostasis. Although U0126 has been suggested to inhibit various cancers, its complete mechanisms have not been clarified in cancers. This review summarized the most recent and relevant research on the many applications of U0126 and described its role and mechanisms in different cancer cell types. Moreover, some acknowledged functions of U0126 researched in the laboratory were listed in our review. We discussed the probability of using U0126 to restain cancers or suppress the MAPK pathway as a novel way of cancer treatment.
U0126作为丝裂原活化蛋白激酶(MAPK)信号通路的抑制剂,与多种生物学过程密切相关,如分化、细胞生长、自噬、凋亡和应激反应。这使得U0126在平衡细胞内环境稳定方面发挥着重要作用。尽管已有研究表明U0126可抑制多种癌症,但其在癌症中的完整机制尚未阐明。本综述总结了关于U0126众多应用的最新相关研究,并描述了其在不同癌细胞类型中的作用及机制。此外,我们的综述还列出了在实验室中研究的U0126的一些公认功能。我们探讨了将U0126作为一种新型癌症治疗方法用于抑制癌症或抑制MAPK通路的可能性。